Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies

BACKGROUND: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. METHODS: PATHW...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Diabetes Endocrinol
Autors principals: Williams, Bryan, MacDonald, Thomas M, Morant, Steve V, Webb, David J, Sever, Peter, McInnes, Gordon T, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Padmanabhan, Sandosh, Mackenzie, Isla S, Salsbury, Jackie, Brown, Morris J
Format: Artigo
Idioma:Inglês
Publicat: The Lancet, Diabetes & Endocrinology 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5966620/
https://ncbi.nlm.nih.gov/pubmed/29655877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-8587(18)30071-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars